

RECEIVED

JAN 12 2004

TECH CENTER 1600/2900

Express Mail Label No. EV 246879918 US  
Attorney Docket No. 4409.214-US  
Serial No. 09/772,607

Attorney Docket No.: 4409.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jonassen et al.

Serial No.: 09/772,607

Group Art Unit: 1653

Filed: January 30, 2001

Examiner: Kam, C.

Confirmation No: 2082

For: Peptide Derivatives

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the time for response to the Office Action dated July 1, 2003 be extended for a period of 3 months from October 1, 2003 to January 2, 2004. Applicant hereby petition for such extension of time.

Please charge the required fee, estimated to be 950.00, with this application and to credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: January 2, 2003

Richard W. Bork  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Express Mail Label No. EV 246879918 US  
Attorney Docket No. 4409.214-US  
Serial No. 09/772,607

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed **after** the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is (*check off either one*)


☐ the statement as specified in 37 C.F.R. § 1.97(e)

**or**

☒ the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: January 2, 2004

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Use the following customer number for all correspondence regarding this application

**23650**

PATENT TRADEMARK OFFICE